Literature DB >> 2066434

Anticardiolipin antibodies in leptospirosis.

F P Rugman1, G Pinn, M F Palmer, M Waite, C R Hay.   

Abstract

The clinical course and serology of 16 cases of leptospirosis in an area with an unusually high endemic infection rate were studied to gain further insight into the pathology of the secondary immune phase that is typical of the disease. IgG anticardiolipin antibody concentrations were measured by immunoassay and found to be increased in eight serologically confirmed cases with severe complicated disease, compared with eight patients with relatively uncomplicated leptospirosis who had IgG anticardiolipin concentrations within the control reference range. This previously unreported association suggests that leptospira may induce vascular endothelial injury in severe cases and expose crypt antigens or induce conformational change of cell surface phospholipids. Leptospirosis may provide a model for an infective origin of some cases of the antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066434      PMCID: PMC496838          DOI: 10.1136/jcp.44.6.517

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Koike
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

2.  Is thrombocytopenia seen in patients with leptospirosis immunologically mediated?

Authors:  A Davenport; F P Rugman; M J Desmond; R Ganta
Journal:  J Clin Pathol       Date:  1989-04       Impact factor: 3.411

3.  Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets.

Authors:  P Hasselaar; R H Derksen; L Blokzijl; P G de Groot
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

4.  Anticardiolipin antibodies in Lyme disease.

Authors:  C G Mackworth-Young; E N Harris; A C Steere; F Rizvi; S E Malawista; G R Hughes; A E Gharavi
Journal:  Arthritis Rheum       Date:  1988-08

5.  Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder.

Authors:  C G Mackworth-Young; S Loizou; M J Walport
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

6.  Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.

Authors:  J Rauch; M Tannenbaum; A S Janoff
Journal:  Thromb Haemost       Date:  1989-11-24       Impact factor: 5.249

7.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

  7 in total
  5 in total

Review 1.  Leptospirosis.

Authors:  P N Levett
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 2.  Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen.

Authors:  Albert I Ko; Cyrille Goarant; Mathieu Picardeau
Journal:  Nat Rev Microbiol       Date:  2009-10       Impact factor: 60.633

3.  Specificity of anti-phospholipid antibodies in infectious mononucleosis: a role for anti-cofactor protein antibodies.

Authors:  M Sorice; V Pittoni; T Griggi; A Losardo; O Leri; M S Magno; R Misasi; G Valesini
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

4.  Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection.

Authors:  U Jaeger; S Kapiotis; I Pabinger; E Puchhammer; P A Kyrle; K Lechner
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

5.  Association Between Severity of Leptospirosis and Subsequent Major Autoimmune Diseases: A Nationwide Observational Cohort Study.

Authors:  Chih-Chung Chen; Yao-Min Hung; Lu-Ting Chiu; Mei-Chia Chou; Renin Chang; James Cheng-Chung Wei
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.